Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

phase icon View trials
by phase
cancer type icon View trials by
cancer type
target icon View trials by
therapeutic target
NILEX=new indication line extension; NME=new molecular entity.

AURKA

Neuroblastoma
LY3295668

BTK

CLL/SLL
BTK Inhibitor Enrolling
Pirtobrutinib, LOXO-305
CLL/SLL or NHL
BTK Inhibitor Enrolling
Pirtobrutinib, LOXO-305
MCL
BTK Inhibitor Enrolling
Pirtobrutinib, LOXO-305

CDK4 & 6

Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer
Abemaciclib, LY2835219
Breast Cancer or NSCLC
Abemaciclib, LY2835219
Pediatric Cancer
Abemaciclib, LY2835219
Prostate Cancer
Abemaciclib, LY2835219
Prostate Cancer
Abemaciclib, LY2835219

IDH1

Advanced Hematologic Malignancies
IDH1 Inhibitor Enrolling
LY3410738
Advanced Solid Tumors
IDH1 Inhibitor Enrolling
LY3410738

PDGFRα

Pancreatic Cancer
Olaratumab, LY3012207, IMC‑3G3
Sarcoma
Olaratumab, LY3012207, IMC‑3G3

RET

Medullary Thyroid Cancer
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
NSCLC
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723
Pediatric Cancer
RET Inhibitor Enrolling
Selpercatinib, LOXO-292, LY3527723

SERD

Breast Cancer or Endometrial Cancer
LY3484356
Breast Cancer
LY3484356

VEGFR2

Advanced Solid Tumors
Ramucirumab, LY3009806, IMC‑1121B
Experimental Dosing
Ramucirumab, LY3009806, IMC‑1121B
Gastric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Gastric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Hepatocellular Carcinoma
Ramucirumab, LY3009806, IMC‑1121B
NSCLC
Ramucirumab, LY3009806, IMC‑1121B
NSCLC
Ramucirumab, LY3009806, IMC‑1121B
Pediatric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Pediatric Cancer
Ramucirumab, LY3009806, IMC‑1121B

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.